GLOBAL HEALTH GRAND ROUNDS
Monday, January 28

Using Clinical Trial to Answer Global Health Challenges in Resource Limited Settings

Lloyd Mulenga, MBChB, MSc, MMed
University of Zambia, Ph.D. Candidate
National HIV Program Coordinator, Zambia Ministry of Health
Director, Infectious Diseases Centre, University Teaching Hospital
Lusaka, Zambia

Trial Title: Virological Impact of Switching from Efavirenz and Nevirapine based first line ART Regimens to Dolutegravir (VISEND)

This is a randomized prospective study among HIV infected individuals on antiretroviral therapy (ART) to evaluate virologic outcomes among patients switching with detectable and undetectable viral loads from a first-line 2 NRTI + NNRTI-based to 2 NRTI + INSTI-based (DTG) regimens in Zambia and Zimbabwe.

Vanderbilt Institute for Global Health
2525 West End Avenue
8th Floor Conference Room
11 a.m. – noon
vumc.org/global-health